International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 4, Issue 3 | Case Report | Open Access DOI

Squamous Cell Lung Carcinoma with ROS1CD74-ROS1 Fusion 76% Rearrangement and PDL-1 50% TPS: A Case Report

Corazon A Ngelangel*

Corazon A Ngelangel1,2*, Mary Kim S Quebec1, Edith Mari Timbol2, Michelle Angela Tan-Reyes1, Emelita S Lapuz1, Joseph Adrian L Buensalido1,2, John Patrick C See1, Enrico Tangco1, Jennifer Sandoval-Tan2

1Asian Hospital and Medical Center-Asian Cancer Institute,

2University of the Philippines-College of Medicine Philippine General Hospital

*Correspondence to: Corazon A Ngelangel 

Fulltext PDF

Abstract

In the Philippines, lung cancer is the 4th most frequent cancer among women. Adenocarcinoma is the predominant histology type among females, worldwide. Squamous cell lung carcinoma is most associated with familial clustering of cancer, particularly among women. ROS1 rearrangements are extremely rare in squamous cell lung carcinoma (less than 0.2% of cases). Squamous cell lung cancer typically has higher PD-L1 expression than adenocarcinoma. Most ROS1-positive tumors do not express PD-L1 and have a low tumor mutational burden. The correlation between ROS1 rearrangements and PD-L1 overexpression is the least investigated among the druggable translocations in NSCLC.

Here is presented a 69-year-old female, nonsmoker with poorly differentiated squamous cell lung carcinoma presenting a massive right upper lung mass adherent to the middle mediastinal structures, with pleural effusion, with ROS1CD74-ROS1 fusion 76% rearrangement and PDL-1 50% TPS, with several co-morbidities and a strong family history of cancer.

Keywords:

Squamous Cell Lung Cancer; ROS-1; PDL-1; Case report

Citation:

Corazon A Ngelangel, Mary Kim S Quebec, Edith Mari Timbol, Michelle Angela Tan-Reyes, Emelita S Lapuz, Joseph Adrian L Buensalido, et al. Squamous Cell Lung Carcinoma with ROS1CD74-ROS1 Fusion 76% Rearrangement and PDL-1 50% TPS: A Case Report. Int Clinc Med Case Rep Jour. 2025;4(3):1-14.